• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, September 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Revolutionary U of A biopsy-reading invention reaches the masses

Bioengineer by Bioengineer
June 8, 2017
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: University of Alberta

A groundbreaking University of Alberta invention that will impact transplant patients' outcomes–and possibly cancer outcomes in the future–is poised to become widely available now that the transplant test has been licensed by life science leader Thermo Fisher.

The diagnostic tool is a major advancement on existing biopsy approaches for transplant organs because it relies on precise gene expression measurement. Called MMDx (Molecular Microscope Diagnostic System), it was created by UAlberta's Philip Halloran and his team.

"We believe this will eventually become the standard of care of people with kidney, heart, lung and liver transplants," said Halloran, whose spin-off company Transcriptome Sciences Inc. announced an exclusive licensing agreement with One Lambda, a Thermo Fisher brand, in late May.

MMDx was more than 30 years in the making, cost $35 million to develop and is ultimately a disruptive technology, explained Halloran.

"This is a story of a team of researchers who believed in the value of something, even though it was paradigm-changing, and who worked diligently to establish scientific foundation in order to convince medical leaders in the field of its effectiveness and to get it into the hands of the public."

There are more than a million organ transplant patients in the world and roughly 150,000 of them are struggling with organ rejection.

"It's vital that clinicians are able to identify the stage of rejection and what drugs to use, and it begins with a biopsy of the organ," said Halloran.

Conventional histology is often 40 per cent incorrect in assessing causes of rejection, whereas MMDx enables much more accurate diagnoses of transplanted organs that are failing by telling doctors what's damaging the organ–whether it's an infection, a recurrent underlying disease, or toxicity to a certain drug–and determining which drugs work.

"We did not just create a test, we're changing the concept of disease and seeing it for the first time," explained Halloran. For example, years ago MMDx enabled Halloran to see that a mechanism was damaging little blood vessels in transplanted organs. After 10 years of convincing establishment, Halloran is recognized as defining antibody-mediated rejection (ABMR) as the major mechanism causing graft loss post-transplant.

Currently, a U of A lab has been processing limited numbers of biopsies sent from centres from around the world.

UAlberta experts have been assisting with the new service at Kashi Clinical Laboratories, in Portland, Ore., which will be able to handle samples worldwide by September, said Halloran.

MMDx is already being considered by other researchers in different fields of medicine. For example, a team of U of A melanoma researchers, led by Michael Smylie at the Cross Cancer Institute, are working with the Halloran team to determine whether the MMDx tool can be used to predict which patients with advanced life-threatening cancer would respond to a life-saving new drug. As well, a U of A ulcerative colitis researcher team, led by Brendan Halloran, are using MMDx to try to understand how molecular change in that disease responds to different therapies.

"MMDx is the heart of precision medicine," said Phillip Halloran, who explained that over time, a repository of individual gene expression statements will be built up in the MMDx computerized database. When a sample is taken and the computer runs comparisons, it can find other patients with nearly identical features whose outcomes have been recorded.

"It's not establishing categories of broad data sets, but measuring the features and predicting the risks of a particular patient," he added.

"This will lead to precise prediction about treatments versus strategies for the average patient that don't take into account individual variables. MMDx tries to understand you and cases exactly like you."

###

Media Contact

Ross Neitz
[email protected]
780-492-5986
@ualberta_fomd

http://www.med.ualberta.ca

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Targeting Cathepsin S Enhances IL-7 Anti-Tumor Immunity

September 3, 2025

Clinician Concerns: Navigating Opioid Management eConsults

September 3, 2025

Prototyping: Enhancing Understanding and Engagement Early

September 3, 2025

Anxiety and Reassurance in Urban Chinese Seniors

September 3, 2025
Please login to join discussion

POPULAR NEWS

  • Needlestick Injury Rates in Nurses and Students in Pakistan

    296 shares
    Share 118 Tweet 74
  • Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    154 shares
    Share 62 Tweet 39
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    143 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    118 shares
    Share 47 Tweet 30

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Targeting Cathepsin S Enhances IL-7 Anti-Tumor Immunity

Clinician Concerns: Navigating Opioid Management eConsults

Prototyping: Enhancing Understanding and Engagement Early

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.